ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Janus kinase (JAK)"

  • Abstract Number: 2084 • 2012 ACR/ARHP Annual Meeting

    ASP015K: A Novel JAK Inhibitor Demonstrated Potent Efficacy in Adjuvant-Induced Arthritis Model in Rats

    Shunji Yamazaki1, Masamichi Inami1, Misato Ito1, Yasutomo Fujii1, Kaori Hanaoka1, Kaoru Yamagami1, Kenji Okuma1, Yoshiaki Morita1, Shohei Shirakami2, Takayuki Inoue2, Susumu Miyata3 and Yasuyuki Higashi1, 1Pharmacology Research Labs, Astellas Pharma Inc., Tsukuba, Japan, 2Chemistry Research Labs, Astellas Pharma Inc., Tsukuba, Japan, 3Research Planning & Administration, Astellas Pharma Inc., Tsukuba, Japan

    Background/Purpose: The Janus kinase (JAK) family of enzymes plays a key role in cytokine signaling, which is involved in the pathogenic events of immune-mediated disorders…
  • Abstract Number: 1697 • 2012 ACR/ARHP Annual Meeting

    Meta-Analysis of Malignancies, Serious Infections, and Serious Adverse Events with Tofacitinib or Biologic Treatment in Rheumatoid Arthritis Clinical Trials

    Sima Ahadieh1, Tina Checchio1, Thomas Tensfeldt1, Jonathan French2, Sriram Krishnaswami1, Richard Riese3, Sujatha Menon1, Mary G. Boy1 and Jamie L. Geier4, 1Pfizer Inc., Groton, CT, 2Metrum Research Institute, Tariffville, CT, 3Pfizer Inc, Groton, CT, 4Epidemiology, Pfizer Inc., New York, NY

    Background/Purpose: Patients with rheumatoid arthritis (RA) experience adverse events (AEs) attributed to both the disease and its treatment. Tofacitinib is a novel oral Janus kinase…
  • Abstract Number: 1322 • 2012 ACR/ARHP Annual Meeting

    Coadministration of ASP015K, a Novel Janus Kinase Inhibitor with Methotrexate Demonstrates Tolerability and Lack of Pharmacokinetic Interactions in Patients with Rheumatoid Arthritis

    Tong Zhu1, Kazuo Oda2, Udaya Valluri1, Bogie Moore1, Ying Cao1, Vishala Chindalore3 and Bola Akinlade4, 1Astellas Pharma Global Development, Inc., Northbrook, IL, 2Drug Metabolism Research Labs. Drug Discovery Research, Astellas Pharma Inc., Osaka, Japan, 3Pinnacle Research Group/Anniston Medical Clinic, Anniston, AL, 4Immunology Development, Astellas Pharma Global Development, Inc., Northbrook, IL

    Background/Purpose: ASP015K is an oral Janus kinase (JAK) inhibitor with selectivity for JAK1/3 in development for treatment of rheumatoid arthritis (RA) and other autoimmune diseases.…
  • Abstract Number: 1297 • 2012 ACR/ARHP Annual Meeting

    Tofacitinib and Adalimumab Achieve Similar Rates of Low Disease Activity in Rheumatoid Arthritis — Lack of Improvement in Disease Activity Score by 3 Months Predicts Low Likelihood of Low Disease Activity At 1 Year

    Ronald F. van Vollenhoven1, Sriram Krishnaswami2, Birgitta Benda3, David Gruben4, Bethanie Wilkinson4, Charles A. Mebus4, Samuel H. Zwillich2 and John Bradley2, 1Karolinska Institute, Stockholm, Sweden, 2Pfizer Inc, Groton, CT, 3Pfizer Inc., Collegeville, PA, 4Pfizer Inc., Groton, CT

    Background/Purpose: Tofacitinib is a novel oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. This post-hoc analysis of the…
  • Abstract Number: 1277 • 2012 ACR/ARHP Annual Meeting

    Tofacitinib, an Oral Janus Kinase Inhibitor, in Combination with Methotrexate Reduced the Progression of Structural Damage in Patients with Rheumatoid Arthritis: Year 2 Efficacy and Safety Results From a 24-Month Phase 3 Study

    D. van der Heijde1, Y. Tanaka2, Roy Fleischmann3, Edward Keystone4, Joel M. Kremer5, C. Zerbini6, M. H. Cardiel7, S. B. Cohen8, P. T. Nash9, Y. Song10, D. Tegzova11, B. Wyman12, D. Gruben12, B. Benda13, G. Wallenstein14, S. Krishnaswami12, S. H. Zwillich12, J. Bradley15, C. A. Connell16 and ORAL Scan Investigators17, 1Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2University of Occupational and Environmental Health, Kitakyushu, Japan, 3Metroplex Clinical Research Center, Dallas, TX, 4Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, Mount Sinai Hospital, Toronto, ON, Canada, 5The Center for Rheumatology, Albany Medical College, Albany, NY, 6CEPIC – Centro Paulista de Investigação Clínica, São Paulo-SP, Sao Paulo, Brazil, 7Centro de Investigacion Clinica de Morelia, Morelia, Mexico, 8Metroplex Clinical Research Centre, Dallas, TX, 9Rheumatology Research Unit, Nambour Hospital, Sunshine Coast, Australia, 10Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea, 11Institute of Rheumatology, Prague, Czech Republic, 12Pfizer Inc., Groton, CT, 13Clinical Development & Medical Affairs, Pfizer Inc., Collegeville, PA, 14Pfizer Inc, New York, NY, 15Worldwide Pharmaceutical Development, Pfizer Inc., Groton, CT, 16Pfizer Inc, Groton, CT, 17Groton

    Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. This 24‑month (Mo) Phase 3…
  • Abstract Number: 1278 • 2012 ACR/ARHP Annual Meeting

    Tuberculosis and Tofacitinib Therapy in Patients with Rheumatoid Arthritis

    Kevin L. Winthrop1, S.-H. Park2, A. Gul3, M. Cardiel4, JJ Gomez-Reino5, D. Ponce de Leon6, R. Riese7, R. Chew7, T. Kawabata7, E. Mortensen6 and H. Valdez8, 1Dept of Infectious Disease, Oregon Health & Science University, Portland, OR, 2The Catholic University of Korea, Seoul, South Korea, 3Istanbul University, Istanbul, Turkey, 4Centro de Investigación Clínica de Morelia SC, Morelia, Mexico, 5Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, 6Pfizer Inc., Collegeville, PA, 7Pfizer Inc., Groton, CT, 8Pfizer Inc., New York, NY

    Background/Purpose: Biologic therapies that block tumor necrosis factor-alpha (TNF) increase the risk of tuberculosis (TB), and screening for latent tuberculosis infection (LTBI) before their initiation…
  • Abstract Number: 1282 • 2012 ACR/ARHP Annual Meeting

    Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Open-Label, Long-Term Extension Safety and Efficacy up to 48 Months

    Jurgen Wollenhaupt1, Joel C. Silverfield2, Eun Bong Lee3, Susan P. Wood4, Koshika Soma5, Lisy Wang4, Hiroyuki Nakamura6, Yoshihiro Komuro6, Chudi I. Nduaka4, David Gruben4, Birgitta Benda7, Samuel H. Zwillich5, Richard Riese4 and John D. Bradley4, 1Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, 2Healthpoint Medical Group, Tampa, FL, 3Seoul National University, Seoul, South Korea, 4Pfizer Inc., Groton, CT, 5Pfizer Inc, Groton, CT, 6Pfizer Japan Inc., Tokyo, Japan, 7Pfizer Inc., Collegeville, PA

    Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy in RA. Here we report the safety…
  • Abstract Number: 1283 • 2012 ACR/ARHP Annual Meeting

    Effects of Tofacitinib On Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis Receiving Stable-Dose Methotrexate: Results of Two Phase 3 Studies

    Gerd Burmester1, Désirée van der Heijde2, Vibeke Strand3, Cristiano A. F. Zerbini4, Carol A. Connell5, Charles A. Mebus5, Samuel H. Zwillich6, John D. Bradley5, David Gruben5 and Gene Wallenstein5, 1Department of Rheumatology and Clinical Immunology, Charité – University Medicine Berlin, Berlin, Germany, 2Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 3Adjunct, Division of Immunology / Rheumatology, Stanford University, Palo Alto, CA, 4Centro Paulista de Investigação Clinica, Sao Paulo, Brazil, 5Pfizer Inc., Groton, CT, 6Pfizer Inc, Groton, CT

    Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. The efficacy and safety of…
  • « Previous Page
  • 1
  • …
  • 11
  • 12
  • 13
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology